Cynata clears key European regulatory step toward future Phase 3 in acute graft versus host disease

Cynata Therapeutics has received a Positive Opinion from the European Medicines Agency’s Paediatric Committee (PDCO) on its ...
GlobalData on MSN

Hansa Biopharma’s Idefrix leads to one-year GvHD survival in kidney transplant

Hansa will apply to the EMA to convert Idefrix’s conditional approval into full marketing authorisation.
Clinical Pain Advisor

Autoimmune Disease Linked to Poor Outcomes With Myelodysplastic Syndrome

HealthDay News — Having a preexisting autoimmune disease is an independent risk factor for poor outcomes with myelodysplastic syndrome (MDS), according to a study published in the June issue of ...

Cynata Nears Key Data Readouts as Pivotal Cell Therapy Trials Advance

Detailed price information for Cynata Therapeutics Ltd (CYYNF) from The Globe and Mail including charting and trades.
Nature

Graft Versus Host Disease in Solid Organ Transplantation

Graft versus host disease (GVHD) following solid organ transplantation is a rare but often fatal complication arising when donor immune cells contained within the graft recognise recipient tissues as ...
Yahoo Finance

Press Release: Sanofi’s Rezurock approved in the EU to treat chronic graft-vs-host disease

Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medicine for patients with limited treatment options Paris, March 31, 2026. The ...
News-Medical.Net

Stem cell transplantation is the most cost-effective sickle cell treatment

Stem cell transplantation is the most cost-effective option for long-term care of sickle cell disease in adults when compared ...